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Abstract 17 
Statins are a class of pharmaceutical widely used to treat high serum cholesterol. In addition, 18 
statins have so-called “pleiotropic effects”, which include the reduction of inflammation, 19 
immunomodulation, and anti-microbial effects. An increasing number of studies are emerging 20 
which detail the attenuation of bacterial growth and in vitro and in vivo virulence by statin 21 
treatment. In this review, we describe the current information available surrounding the effects of 22 
statins on bacterial infections, and provide insight regarding the potential use of these 23 
compounds as anti-microbial therapeutic agents.  24 
25 
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Introduction 26 
One of the major undisputed clinical breakthroughs of the 20th century was the discovery of the 27 
statin family of drugs. These compounds are renowned for their ability to lower cholesterol 28 
levels, and are used to treat approximately 40 million individuals with high cholesterol 29 
worldwide. Since the discovery of mevastatin as a metabolic product of Penicillium citrinum in 30 
1976 (1, 2) a total of nine statins have been characterized, seven of which are approved by the 31 
FDA to treat patients with high cholesterol. Structurally, statins are characterized by the presence 32 
of a conserved lactone ring (3). This structure is present as a hydrolyzed (active) form in all 33 
statins except for mevastatin, lovastatin and simvastatin, where the lactone ring is hydrolyzed in 34 
the liver (4). Statins can be divided into two broad classes (Figure 1). Type 1 statins are 35 
lipophilic, and possess a butaryl side chain – they are said to structurally resemble mevastatin 36 
(3). Lovastatin, pravastatin and simvastatin are type 1 statins. Type 2 statins are classically 37 
lipophobic, and are distinguished from type 1 by the replacement of the butaryl side chain with a 38 
fluorophenol group and typically possess larger side chains than type 1 statins (3). Atorvastatin, 39 
cerivastatin, fluvastatin, pitavastatin and rosuvastatin are type 2 statins.  40 
Statins exert their cholesterol lowering effect by binding to the active site of 3-hydroxy-3-41 
methylglutaryl-CoenzymeA reductase (HMGR), a rate-limiting enzyme involved in cholesterol 42 
biosynthesis (3). HMGR is an integral part of the mevalonate pathway, which is not only 43 
essential for cholesterol biosynthesis, but also contributes to the production of isoprenoids, lipid 44 
compounds that are essential for cell signaling and structure. As well as the inhibition of 45 
cholesterol, statins have also been found to have a number of cholesterol-independent, so-called 46 
“pleiotropic” effects. Statins have been reported to confer anti-inflammatory, 47 
immunomodulatory and anti-cancer effects on host cells, and these effects are well-characterized 48 
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(5–9). Furthermore, several studies have explored the pleiotropic effects of statins in combating 49 
multi-system microbial infections, such as sepsis and pneumonia, and a growing number of 50 
studies are demonstrating that statins can directly influence the growth and virulence of bacterial 51 
pathogens. With the global increase in antibiotic resistance to existing antibiotics and the search 52 
for new anti-microbial strategies reaching a critical stage, there is increasing interest in the 53 
possibility of repurposing existing drugs that have already been approved to treat different 54 
clinical conditions but that also possess antimicrobial activity. The repurposing of these drugs 55 
would significantly reduce the lead-time from bench to bedside. Given their pleiotropic activities 56 
statins are strong potential candidates to be repurposed as novel antimicrobial agents. However, 57 
the evidence for this remains controversial owing to the number of apparently contradictory 58 
studies. This review evaluates and discusses the effects of individual statins on bacterial growth 59 
and virulence and bacterial infections in the context of pathogen-host interactomes (summarized 60 
in Figure 2). 61 
 62 
Clinical evidence that statins influence morbidity and mortality of patients with microbial 63 
infections.  64 
The clinical potential of statins as anti-microbial agents has been the subject of several studies 65 
and reviews. A number of meta-analyses of cohort studies on the impact of overall statin use on 66 
different infection outcomes showed positive findings, albeit while highlighting the limitations 67 
and heterogeneity of the studies (10 - 13). These reviews included studies on infections such as 68 
bacteraemia, pneumonia, sepsis and some acute infections and patient populations received 69 
several different statins. For instance, two single centre retrospective studies showed that patients 70 
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with bacteraemia who have undergone prior statin treatment have a significant decreased risk of 71 
in hospital mortality of 6% vs 28% (p = 0.002) and 13% vs 24% (p = 0.001) respectively (14, 72 
15). The latter study also showed there was an inverse correlation between the length of statin 73 
treatment and risk of mortality when they compared statin use ≥12 and <12 weeks prior to 74 
infection (11% vs 14%, p = 0.04)  (15). A meta analysis of available published data found that 75 
the use of statins was specifically associated with a reduced risk of morbidity and mortality 76 
resulting from pneumonia (12). A retrospective study of patients in the UK found that current 77 
statin treatment (within last 30 days) reduced pneumonia-associated mortality (adjusted OR 0.47, 78 
95% CI 0.25-0.88) (16), while prior statin treatment also reduced mortality rates in patients in the 79 
USA with community-acquired pneumonia (CAP) (adjusted OR 0.36, 95% CI 0.14–0.92) (17). 80 
Furthermore, data from the Justification for the Use of Statin in Prevention: An Intervention 81 
Trial Evaluating Rosuvastatin (JUPITER), which was initially undertaken to determine whether 82 
rosuvastatin could reduce the risk of cardiac disease in people without hyperlidemia (18) were 83 
retrospectively analysed in 2012. This analysis suggested that rosuvastatin treatment may 84 
decrease the occurrence of pneumonia before (HR 0.81, 95% CI 0.67–0.97) or after a cardiac 85 
event (HR 0.83, 95% CI 0.69–1.00) (19). In contrast however, an earlier prospective cohort study 86 
which examined adults in six Canadian hospitals had concluded that after adjusting for 87 
confounding factors such as the ‘healthy user effect’ prior statin treatment does not yield reduced 88 
mortality from pneumonia (20). This latter study encompassed 3415 patients >17 yrs of age with 89 
pneumonia admitted to hospital, while the JUPITER randomized, double-blind, placebo-90 
controlled trial of 17,802 healthy patients was restricted to men >50yrs and women >60yrs of 91 
age. Indeed, the JUPITER study was designed to address the ‘healthy user effect’ suggesting that 92 
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study design in addition to age differences between the cohorts may underpin the contrasting 93 
observations.  94 
Sepsis is a serious infection-induced whole body inflammatory state, and due to the 95 
immunomodulatory activity of statins, several studies have been carried out to evaluate the 96 
benefit of statin therapy in the prevention or treatment of the disease. While the type, design, size 97 
and measured outcomes of the studies have been varied and overall results conflicting, in recent 98 
years extensive reviews evaluating these clinical studies have been published (21-27). The 99 
majority of clinical studies to date have been retrospective cohort studies evaluating the impact 100 
of prior treatment with statins on disease progression and mortality. Many of these, plus several 101 
meta-analysis reviews, showed promising results whereby prior use of statins significantly 102 
reduced disease progression and/or mortality associated with sepsis (25, 28 - 32). For instance, 103 
studied by Almog et al. and Martin et al. demonstrated a reduced risk of developing severe sepsis 104 
in patients pretreated with statins (2.4% vs 19%, P<0.001 and 56% vs 86%, P<0.02 respectively) 105 
while Mortensen et al. showed a reduced risk of 30 day mortality in patients using statins (OR 106 
0.48, 95% CI 0.36-0.64). One of the main limitations attributed to these studies was limited 107 
sample size, and against this, a recent population-based, propensity score-matched analysis of the 108 
effect of low and high doses of statins on sepsis outcomes involved a cohort of 27,792 statin 109 
users compared with an equal number of non-users (33). This extensive study demonstrated a 110 
significant reduction of 1-year mortality (HR 0.83, 95 % CI 0.81–0.85) and adverse 111 
consequences of sepsis such as in-hospital death (OR 0.86, 95 % CI 0.83–0.89) and ICU 112 
admission (OR 0.95, 95 % CI 0.92–0.98) in patients pretreated with statins. They also showed 113 
that the benefits of pretreatment with statins increased significantly with higher doses.  114 
Therefore, several studies have shown promising potential for the prior use of statins in the 115 
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prevention / progression of infections. Nevertheless, it is difficult to draw conclusions on 116 
whether these statins effects were directly anti-bacterial / inflammatory or due to pleitrophic 117 
effects on co-morbitities associated with the infections. For example, it is estimated that 118 
cardiovascular events account for up to 30% of deaths in patients with CAP and therefore it 119 
could be argued that prior statin use could improve cardiovascular health and thus reduce 120 
mortaliry rather than having any direct efect on the infection. Against this a study has reported 121 
that while prior statin use was significantly associated with decreased 90-day mortality in CAP 122 
patients, there was no significant association with cardiocasular events (34). In order to fully 123 
understand the mechanistic effects of prior statin use on infections similar studies targeting for 124 
example specific co-morbidities and/or inflammatory markers would be required.   125 
In contrast to prior use of statins, however, studies investigating the benefits of de-novo 126 
treatment of infections with statins have generally not shown favorable results. A recent 127 
randomized control trial (RCT) investigating the effect of rosuvastatin on the clinical outcome of 128 
patients with sepsis associated acute respiratory distress syndrome was discontinued because of 129 
futility (35).  Moreover, a number of recent meta-analyses of RCTs suggest that there is no 130 
significant evidence to suggest that statin use improves the mortality outcome of patients with 131 
sepsis (25 - 27).  132 
Further large scale RCT research is also recommended to evaluate the efficacy of using de-novo 133 
statin therapy to treat specific infections. Of particular note is that the majority of the studies 134 
reviewed so far did not adjust for the type of statin used or the type of bacteria causing the 135 
infection. An interesting study of the effect of prior statin use on mortality in patients with 136 
bloodstream infections found a significant reduction in 90-day mortality in statin users with 137 
Gram-negative infections (adjusted OR 0.38, 95 % CI 0.20–0.72, P=0.003) but no significant 138 
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difference in statin users with Gram-positive infections (adjusted OR 1.22, 95% CI 0.69–2.17, 139 
P=0.49) (36), suggesting that the type of bacterial infection may be a significant factor.  140 
 141 
Effects of statins on in vitro bacterial growth. 142 
There is a large body of evidence demonstrating that statins have direct anti-bacterial effects on 143 
the in vitro growth of both Gram-positive and Gram-negative bacterial pathogens responsible for 144 
a wide range of infections (Table 1), although there have been conflicting reports on MICs 145 
(ranging from 15 mg/l to 500 mg/l) and strain specificity may be a factor (Table 1). The growth 146 
of the Gram-positive nosocomial pathogens Staphylococcus aureus and Streptococcus 147 
pneumoniae has been shown to be inhibited by atorvastatin, rosuvastatin and simvastatin (37–148 
43), while fluvastatin has also been reported to inhibit the growth of S. aureus (37). In addition, 149 
both type 1 (simvastatin) and type 2 (atorvastatin, fluvastatin and rosuvastatin) statins have also 150 
demonstrated a bacteriostatic effect against other Gram-positive cocci, notably Streptococcus 151 
pyogenes, Staphylococcus epidermidis, Enterococcus and Bacillus spp. (37, 39, 40, 42).  152 
Promisingly, simvastatin, lovastatin and rosuvastatin have also been shown to have anti-bacterial 153 
effects on the growth of antibiotic-resistant species such as methicillin-resistant S. aureus 154 
(MRSA), vancomycin-resistant S. aureus (VRSA) and vancomycin-resistant enterococci (VRE), 155 
although the MIC concentrations are typically higher than against antibiotic sensitive strains 156 
(Table 1) (37, 39 - 43).  157 
Both type 1 and type 2 statins have also been found to inhibit the growth of a number of 158 
clinically important Gram-negative species including several respiratory pathogens. The growth 159 
of the nosocomial respiratory pathogens Pseudomonas aeruginosa, Acinetobacter baumanii and 160 
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Klebsiella pneumoniae is inhibited by atorvastatin, rosuvastatin and simvastatin (MICs ranging 161 
from 15 - 333 mg/l) (39, 40) and simvastatin was reportedly bactericidal against Moraxella 162 
catarrhalis (MIC 15 mg/l) (38). In addition to respiratory pathogens, statins have also been 163 
reported to inhibit other Gram-negative nosocomial pathogens. Masadeh et al. reported that 164 
atorvastatin, rosuvastatin and simvastatin have bacteriostatic effects against a range of pathogens 165 
including Citrobacter freundii, Enterobacter aerogenes, Haemophilus influenzae and Proteus 166 
mirabilis (MICs ranging from 15 - 166 mg/l) (39). Simvastatin and lovastatin (10 mg/l) are also 167 
reportedly bactericidal against the spirochete Borrelia burgdorferi (the causative agent of Lyme 168 
disease) (44) and atorvastatin, rosuvastatin and simvastatin were found to inhibit the growth of 169 
Escherichia coli, a prominent cause of gastroenteritis and urinary tract infections (39). In 170 
contrast, however, Bergman et al., using a maximum concentration of 250 mg/L observed that  171 
simvastatin did not inhibit the growth of H. influenzae (38), while Graziano et al. found that 172 
simvastatin, atorvastatin and pravastatin at concentrations up to 250 mg/l did not inhibit the 173 
growth of P. aeruginosa, E. coli or Enterococcus faecalis (43). Furthermore, the study by 174 
Thangamani et al. (42) reported that while the growth of Gram-positive species was inhibited by 175 
statins, the growth of P. aeruginosa ATCC 15442 was not inhibited by the statins simvastatin, 176 
atorvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin or rosuvastatin. They 177 
also reported that simvastatin did not inhibit the growth of a range of other Gram-negative 178 
pathogens including different strains of P. aeruginosa, K. pneumoniae, A. baumanii, E. coli and 179 
Salmonella enterica serovar Typhimurium. Interestingly, they did show that when combined 180 
with sub-inhibitory concentrations of colistin, which compromises the outer membrane integrity, 181 
simvastatin had anti-bacterial activity against the range of Gram-negative pathogens at MICs of 182 
8 – 32 mg/l. While the activity shown by simvastatin against E. coli ATCC35218 (39) is in direct 183 
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contrast to the lack of activity by simvastatin against E. coli ATCC35150, ATCC 700728, 184 
ATCC25922, and ATCC10536 (42-43), it is worth noting that the E. coli ATCC3218 assays 185 
were performed on solid agar while the other studies were performed using the broth 186 
microdilution method, perhaps explaining the apparent differences in activity. 187 
Taken together, the data suggest that the anti-bacterial activity of statins may be both statin 188 
specific and / or strain/species specific. Simvastatin and atorvastatin generally appear to be more 189 
effective against S. aureus, S. pneumoniae and enterococci than other statins (37–40), while three 190 
distinct simvastatin MICs were reported against S. aureus clinical isolates from the UK and 191 
Jordan as well as typed reference strains (Table 1) (37, 39, 42, 43). It is also noteworthy that 192 
while the MICs of statins varied according to statin and pathogen tested, the in vitro MICs 193 
ranged from circa 15 to 400 mg/l, which far exceeds the typical peak plasma concentrations of 194 
patients on oral statins, which generally ranges from circa 10 to 300 µg/l. Moreover, in the 195 
majority of cases the in vitro statin MICs against multi-drug resistant pathogens were even 196 
greater than those against equivalent antibiotic susceptible strains. As such, at these MIC 197 
concentrations, it is unlikely that they would qualify as lead molecules in drug discovery 198 
programs. This variability in MICs could be considered somewhat unexpected for what is 199 
essentially a novel antibiotic compound being administered to a naive population. However, 200 
recent studies have reported significant phenotypic and genotypic diversity within clinical 201 
populations suggesting that adaptation to environmental or host related factors may be 202 
widespread (45 - 47). While the mechanism of action of statin antimicrobial and anti-virulence 203 
activity remains to be elucidated, some reports suggest the involvement of isoprenoids and 204 
membrane integrity (48). Further deciphering the interaction between statins and the microbial 205 
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membrane may provide answers to this apparent heterogeneity, although other targets within the 206 
microbial cell must also be considered. 207 
However, two studies have recently demonstrated the in vivo clinical efficacy of locally high 208 
concentrations of statins whereby topical applications of simvastatin at MIC / sub-MIC 209 
concentrations significantly enhanced bacterial clearance and healing of MSSA and MRSA S. 210 
aureus-contaminated wounds in mice wound models (41, 42). Wang et al. showed that 211 
application of simvastatin (62.5 mg/l) reduced the MSSA wound size by over 50% at day seven 212 
and significantly reduced (>60% reduction) the bacterial load visible in the wound histology 213 
(41), while Thangamani et al. showed that topical simvastatin at concentrations of 1% and 3% 214 
significantly reduced the bacterial load in MRSA wounds by 75% and 90% respectively (42). 215 
The latter study also showed that this topical application of simvastatin had an additive healing 216 
effect and it reduced the production of pro-inflammatory cytokines (IL-6, TNF-α and IL-1β) in 217 
MRSA infected wound lesions.  218 
The mechanism by which statins inhibit bacterial growth is unclear. As previously described, 219 
statins inhibit the mevalonate pathway in human cells. This pathway is present in higher 220 
eukaryotes, as well as several bacterial species including staphylococci and streptococci. 221 
However, not all bacteria possess a mevalonate pathway, and in these species (and in plants) 222 
isoprenoid metabolism is mediated through the 2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-223 
xylulose 5-phosphate (MEP-DOXP) pathway, which is mevalonate-independent (49, 50). The 224 
MEP-DOXP and mevalonate pathways both feed into the production of isoprenoid intermediates. 225 
Generally, it appears that Gram-positive bacteria tend to possess a mevalonate pathway, while 226 
Gram-negative species utilize mevalonate-independent isoprenoid biosynthesis, although there 227 
are some exceptions to this observation. Statins have been shown to inhibit the growth of S. 228 
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aureus by binding to and inhibiting the activity of its HMGR enzyme (51) and this may to some 229 
extent explain why Gram-positive bacteria tend to be more sensitive to statins. However, statins 230 
can attenuate the growth of bacteria irrespective of the presence of HMGR, although the 231 
mechanism is unknown and studies have reported equivalent statin MICs in species with and 232 
without HMGR (39, 40) .  233 
 234 
Effects of statins on intracellular growth of bacteria 235 
The effect of statins on the intracellular growth of pathogens has also been studied and, at drug 236 
concentrations closer to physiological levels, they have been shown to reduce the growth of 237 
several obligate intracellular bacterial pathogens. Recent reports demonstrated that lovastatin at 238 
0.4 mg/l (52) and both atorvastatin and simvastatin, in a dose-dependent fashion (0.08 – 0.8 239 
mg/l), reduced the survival of the leprosy-causing species Mycobacterium leprae (by up to 90% 240 
and 75% respectively) in in vitro macrophage models, but in a cholesterol-dependent manner 241 
(53), suggesting an indirect effect on cholesterol levels as the intracellular growth of these 242 
pathogens requires cholesterol. Prior but not concomitant treatment of murine fibroblast (L929) 243 
cells with lovastatin at 0.4 mg/l also reduced both the intracellular growth of the respiratory 244 
pathogen Coxiella burnetti (which causes Q fever) (by 43%, P=0.064) (54), and plaque 245 
formation by the causative agent of Rocky mountain spotted fever, Rickettsia conorii (by 64%, 246 
P=0.003) (55). Interestingly, in in vivo studies the hydrophobic statin, simvastatin, at a 247 
physiological concentration (0.5mg/kg), but not the hydrophilic statin pravastatin significantly 248 
decreased (up tp 83%) the levels of the respiratory pathogen Chlamydiae pneumoniae in lung 249 
cells of infected mice (56, 57). It was also found that cerivastatin (0.1 mg/l) reduced the cross 250 
infection of VSMC (vascular smooth muscle cells) by C. pneumoniae infected macrophages (56, 251 
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58). In these studies the authors also suggest that the reduced growth may be an indirect effect 252 
due to cholesterol inhibition. 253 
A number of studies report inhibition of the non-obligate intracellular growth of Mycobacterium 254 
tuberculosis in peripheral blood mononuclear cells (PBMCs) and macrophages. Parihar et al. 255 
demonstrated that M. tuberculosis growth was significantly reduced (circa 2-fold, P<0.05) in 256 
human mononuclear cells and macrophages taken from atrovastatin-treated patients with familial 257 
hypercholesterolemia compared with healthy donors while also showing that simvastatin (20.6 258 
mg/l) significantly reduced (circa 3-fold, P<0.01) M. tuberculosis growth in murine macrophages 259 
and both simvastatin and rosuvastatin significantly decreased (circa 2 to 10 –fold P<0.05 /0.01) 260 
the bacterial load in the liver, spleen and lungs of infected mice (20 mg/kg) (59). The study 261 
further demonstrated that the simvastatin-mediated decrease in bacterial growth was reversed by 262 
mevalonate, the product of HMG-CoA reductase and suggested that statins control infection by 263 
phagolysosomal arrest of M. tuberculosis. These results were corroborated by the study by 264 
Lobato et al. whereby they showed that atorvastatin and simvastatin (2 µM) significantly 265 
inhibited M. tuberculosis growth (circa 60% reduction) in macrophages and again this was 266 
reversed by mevalonate (53). A previous study by Parihar et al. also demonstrated that 267 
simvastatin treatment (20.6 mg/l) could significantly reduce, by up to 4-fold, (P<0.001) the 268 
ability of the food borne pathogen Listeria monocytogenes to grow inside mouse and primary 269 
macrophages, in a cholesterol dependent manner and significantly reduce the bacterial burden 270 
and dissemination (by 100-fold) to the liver (P<0.001) and spleen (P<0.05) in infected mice (60). 271 
The intracellular growth of another food borne bacteria, the gastroenteritis-causing Salmonella 272 
enterica serovar Typhimurium, was also attenuated more than 10-fold by lovastatin (50 nM & 30 273 
µM) treatment of murine macrophages, at least in part due to attenuation of the mevalonate 274 
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pathway (61). A key mechanism behind the attenuation of internalized bacterial infections by 275 
statins appears to be the statin-mediated inhibition of lipid raft formation. Lipid rafts are 276 
glycoprotein domains present in the cell membrane, which are formed as a result of cholesterol 277 
spontaneously interacting with sphingoglycolipids. Bacteria can manipulate lipid rafts in order to 278 
invade and survive within cells and induce apoptosis (62). However, statins are known to inhibit 279 
the formation of lipid rafts due to inhibition of cholesterol biosynthesis (63). Two studies 280 
investigating the effects of statins on the intracellular growth of L. monocytogenes and plaque 281 
formation of R. conorii suggest their findings were due to the inhibition of lipid raft formation by 282 
statins (55, 60). 283 
As well as inhibiting intracellular growth, statin treatment at physiological concentrations also 284 
promotes increased bacterial killing in host cells. Simvastatin significantly reduced the burden of 285 
S. pneumoniae in the lungs of infected mice (dose = 1 / 10 mg/kg/day, 50/100-fold reduction, 286 
P=0.02 / 0.002) (64) and significantly increased bacterial clearance (65% reduction, P=0.01) and 287 
reduced dissemination (90% reduction, P=0.01) of S. aureus in a mouse model of pneumonia 288 
(dose = 0.25 mg/kg/day) (65). Simvastatin (~ 41.7 mg/kg/day) also reduced S. aureus recovery 289 
by circa 35 % from mouse peritoneal (P<0.005) and by 2-fold in lung cells (P<0.05) and 290 
mevastatin (50 µM) significantly reduced (40% reduction, P<0.005) the amount of S. aureus 291 
recovered from intracellular infection of human neutrophils and mouse macrophages (66). In this 292 
latter study evidence suggests that there was no direct effect on bacterial viability but that statins 293 
promoted bacterial killing by inducing the formation of phagocyte extracellular traps.  294 
Therefore, evidence suggests that, while the mechanisms by which physiological concentrations 295 
of statins influence intracellular or in vivo bacterial infections are not fully understood, most 296 
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studies suggest indirect action mainly due to pleiotropic effects of modulating the mevalonate 297 
pathway in the host. 298 
 299 
Effects of statins on bacterial virulence 300 
An interesting development in the field of statins and bacterial infection is the discovery that sub 301 
lethal doses of statins may influence bacterial virulence, raising the possibility that statins may 302 
be repurposed as specific anti-virulence therapeutics. A number of studies have investigated the 303 
impact of statin treatment on in vitro bacterial virulence (Table 2). Wang et al. and Graziano et 304 
al. both showed that S. aureus biofilm formation is inhibited by simvastatin (41, 43) while 305 
Hennessy et al. demonstrated that both the in vitro motility and early biofilm formation of the 306 
predominant cystic fibrosis-associated pathogen P. aeruginosa are attenuated by statin 307 
concentrations sub-inhibitory to growth (4 & 40 mg/l respectively) (67). Graziano and colleagues 308 
also showed that simvastatin (4x MIC) could disrupt established S. aureus biofilms and 309 
Thangamani et al. demonstrated that simvastatin at 2x and 4x MIC concentrations reduced 310 
established biofilms of both S. aureus and S. epidermidis by approximately 40% (42, 43). This 311 
latter study by Thangamani et al. also showed that simvastatin suppressed the production of the 312 
S. aureus toxins Panton-Valentine leucocidin (PVL) and α-hemolysin (Hla) produced by MRSA. 313 
They also showed that simvastatin inhibited bacterial protein synthesis and suggest that the 314 
reduction in toxin production may be a reflection of this. 315 
In cell culture studies, simvastatin (4 mg/l) significantly increased (P≤0.05) the adhesion of P. 316 
aeruginosa to lung cells (68) but the translocation of P. aeruginosa across the apical membrane 317 
of kidney cells was significantly inhibited (P<0.05) by simvastatin treatment (5 μM / 2 mg/l) 318 
(69). Neither of these studies observed an alteration in the invasive potential of P. aeruginosa in 319 
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the presence of statin, however, the invasion of other pathogens is inhibited by statins. Horn et al. 320 
demonstrated reduced invasion of S. aureus into vascular epithelial cells in the presence of 321 
physiological concentrations of simvastatin (0.04 - 0.4 mg/l) (70), while mevastatin (4 mg/l) 322 
completely inhibited the internalization of Group B Streptococcus, a common cause of 323 
meningitis, into HeLa cells (71), and attenuated the invasion of E. coli into bladder epithelial 324 
cells (72). In these latter studies inhibition of bacterial invasion was proposed to be due to the 325 
ability of simvastatin and mevastatin to inhibit the activation of Rho GTPase proteins as a result 326 
of the inhibition of the production of the isoprenoid intermediates farnesyl-pyrophosphate and 327 
geranylgeranyl-pyrophosphate, which are required for the prenylation and activation of Rho 328 
GTPases (73).  329 
Therefore, there is promising evidence that statins may influence the invasiveness and/or biofilm 330 
formation of some pathogens, however, a number of studies have observed the absence of statins 331 
affecting other bacterial virulence factors (Table 2). Bacterial cell-cell communication may not 332 
be impacted by statins as simvastatin, lovastatin and mevastatin failed to alter N-acyl-333 
homoserine lactone (AHL) or PQS quorum sensing by P. aeruginosa and mevastatin failed to 334 
alter AHL signaling by Burkholderia cenocepacia, both prominent causes of respiratory 335 
infections in cystic fibrosis patients (67, 74). In the same studies transcription of the exoS Type 336 
Three Secretion toxin and protease production, respectively, were not altered by the statins 337 
tested. Furthermore, an in-depth study carried out using S. pneumoniae demonstrated that sub-338 
inhibitory concentrations of simvastatin (1 mg/l) did not directly influence the activity of the 339 
pneumolysin toxin against red blood cells (75). However, the same study showed that 340 
simvastatin did protect vascular endothelial cells from pneumolysin-induced cytotoxicity in 341 
vitro. This protective effect was reversed by mevalonate, again suggesting an indirect effect. The 342 
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protection was confirmed in vivo whereby it extended to reduced lung damage and increased 343 
survival in a mouse model of infection. 344 
Indeed, several studies have shown that statins can reduce the impact of bacterial toxins on host 345 
cells. In a study that utilized S. aureus α-toxin, leukocyte recruitment and adhesion in mice was 346 
attenuated by simvastatin pretreatment (100 μg/kg) by >70% (P<0.01) (76). This finding is 347 
significant as it suggests that statins may reduce α-toxin-mediated inflammation and 348 
cardiovascular damage. In addition, lovastatin (1 mg/l) improved the survival of mice which 349 
were exposed to another S. aureus toxin, enterotoxin B by 50% (77) and the cytotoxicity of 350 
Bacillus anthracis lethal toxin against macrophages was reduced >60% by fluvastatin, 351 
mevastatin, and simvastatin (78).  352 
The protective mechanism(s) of statins against bacterial virulence has not been established, 353 
however, the impact of statins on host cell isoprenoid metabolism appears to regulate at least 354 
some of the effects observed on bacterial virulence in cell culture and infection models. Several 355 
studies have shown that the observed statin effect on bacterial virulence can be reversed by the 356 
addition of exogenous mevalonate (53, 58-60, 66, 70, 75, 77, 79), while statin-mediated 357 
cholesterol depletion is protective against bacterial toxins (75, 60) and contributes to the killing 358 
of intracellular bacteria (44, 53, 59 - 61, 66). In addition, the regulation of the inflammatory 359 
response by statins may account for some of these protective effects. For instance, cerivastatin 360 
treatment attenuated the production of pro-inflammatory mediators and superoxide in 361 
macrophages infected with C. pneumoniae, and this was associated with a reduced bacterial 362 
infection rate (79). The inflammatory response in lipopolysaccharide-treated mice was also 363 
reduced by cerivastatin treatment, leading to improved survival (80), while simvastatin treatment 364 
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reduced both lung injury and the production of pro-inflammatory chemokines in a mouse sepsis 365 
model (81). 366 
 367 
Co-prescription of statins with antibiotics 368 
It has been hypothesized that physiological or sub-inhibitory doses of statins could be used in 369 
combination with antibiotics to increase the efficacy of treatment. Many researchers have 370 
proposed dual action combinations that remove the virulence threat, either toxin or biofilm, 371 
facilitating clearance by the antibiotic. Indeed, the growing evidence for the effectiveness of next 372 
generation anti-virulence approaches has been tempered by a realization that conventional 373 
antibiotics will still be required to clear the infecting pathogen and resolve the infection.  Current 374 
information on the synergistic relationship between statins and antibiotics is limited and 375 
conflicting (Table 2). A significant synergistic effect resulting in increased bacterial lysis has 376 
been reported with sub-lethal doses of penicillin and simvastatin (7.8 mg/l) against 377 
pneumococcal growth in vitro (38), while atorvastatin and simvastatin (0.2 μM) increased the 378 
efficacy of rifampin against M. tuberculosis and M. leprae infection in vitro by approximately 379 
50% (53). In addition, in vivo mice studies showed that atorvastatin (80 mg/kg/day) increased the 380 
efficacy of rifampin against M. leprae infection (P<0.05) (53) and simvastatin (25 mg/kg) 381 
increased the in vivo activity of first-line anti-TB antibiotics reducing the lung bacillary burden 382 
by >1 log10 (P<0.01) (82). Thangamani and colleagues demonstrated a positive synergistic effect 383 
of simvastatin on the anti-microbial effect of four topical antibiotics, mupirocin, fusidic acid, 384 
retapamulin and daptomycin, against clinical isolates of multi-drug resistant S. aureus. However, 385 
Graziano et al. showed there was no synergistic effect between simvastatin and vancomycin 386 
against S. aureus (43). A recent study, which examined the in vitro effects of five statins, at 387 
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concentrations equivalent to recommended physiological doses (simvastatin, lovastatin, 388 
atrovastatin, pravastatin = 0.01, 0.05, 0.1 mg/l; fluvastatin = 0.1, 0.2, 0.3 mg/l), on the MICs of 389 
six antibiotics against four clinically important Gram-negative strains – P. aeruginosa, A. 390 
baumanii, E. coli and K. pneumoniae – found that the statins did not significantly change the 391 
susceptibilty of any of these bacteria to any of the antibiotics tested (83). However, this in vitro 392 
study may not reflect the true activity in an in vivo setting and therefore further in vivo 393 
investigations are warranted. This is particularly relevant given that the majority of the studies 394 
reviewed here that looked at the mechanism by which statins influence bacterial growth or 395 
virulence in vivo suggest indirect effects as a result of interactions with host cells. In addition, the 396 
anti-biofilm activity of statins towards Gram-negative pathogens, which would be expected to 397 
reduce the MIC of antibiotics in biofilm forming populations (accounting for approximately 80% 398 
of all infections), would not be reflected in the planktonic in vitro MIC assays performed. 399 
It is important to note, however, that the repurposing of statins for use as combinatorial 400 
antibiotics would rely on their compatibility with currently administered antibiotics. While data 401 
in this aspect of antimicrobial therapy is limited, certain antibiotics may interfere with the 402 
metabolism of statins which can lead to increased serum levels and thus an increased risk of 403 
adverse effects (84). For instance, certain statins including simvastatin, lovastatin, and 404 
atorvastatin are metabolised by cytochrome P450 3A4 (CYP3A4) isoenzymes and studies have 405 
shown that co-prescription with drugs that inhibit CYP3A, such as macrolide antibiotics, can 406 
lead to increased adverse effects including rhabdomyolysis in elderly patients (85-92).  In light 407 
of this the US FDA has stated that ‘caution should be exercised when prescribing clarithromycin 408 
with statins’ and in particular ‘concomitant use of clarithromycin with lovastatin or simvastatin 409 
is contraindicated’ (89). In contrast they suggest that the concomitant use of statins not 410 
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dependent on CYP3A metabolism (e.g. fluvastatin) could be considered. However, a recent study 411 
by Li and colleagues demonstrated significantly increased adverse effects when clarithromycin 412 
was co-prescribed with statins not metabolized by CYP3A4 (94), suggesting additional 413 
mechanisms of drug interactions independent of the CYP3A4 pathway, possibly related to 414 
impaired hepatic uptake of statins. In contrast to studies on macrolide-statin interactions, no 415 
additive harmful effects have been attributed to the combined use of statins and the lipopeptide 416 
antibiotic daptomycin, despite both agents being associated with muscle injury (95). 417 
 418 
Summary 419 
The repurposing of statins as anti-microbial agents held promising potential when clinical studies 420 
revealed that patients on cholesterol lowering statins showed improved outcomes from bacterial 421 
infections. However, as outlined in this review the most convincing evidence of significantly 422 
improved infection outcomes is when patients are pretreated with statins and the anti-microbial 423 
effect is probably indirect. There is little evidence of significantly improved outcomes when 424 
infections are treated with de-novo statins. However, while the evidence for statin effectiveness 425 
thus far has been provided from prophylactic studies, the anti-virulence activity emerging for 426 
statins, whereby pathogens may be silenced rather than killed, offers an alternative perspective 427 
on their potential clinical utility. In addition, statins may also offer selectivity in targeting 428 
pathogenesis rather than the microbial population or microbiome as a whole, which is a major 429 
factor in maintaining host homeostasis. This could have the added advantage of removing the 430 
selective pressure that underpins the continued spread of antibiotic resistance among populations. 431 
Thus, further RCTs and prospective studies have been recommended and based on this review 432 
the design of these new studies will be crucial as in vitro and mouse studies clearly show that the 433 
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most gain may be achieved by matching particular statins with particular infecting pathogens. 434 
Moreover, one of the most limiting factors is the concentration of statins required for the 435 
inhibition of bacterial growth in vitro. In almost all cases cited the in vitro MICs far exceed the 436 
general plasma levels found in patients receiving cholesterol-lowering statins and the feasibility 437 
of raising the dose is questionable due to cytotoxicity and increased risk of debilitating side 438 
effects. One area where specific targeted studies may be particularly beneficial is in the treatment 439 
of infections caused by intracellular pathogens. Many in vitro cellular studies outlined here show 440 
significant results when using statins at physiological concentrations, while again suggesting the 441 
effect is indirect. It would be interesting to see if these beneficial effects could be mimicked in in 442 
vivo clinical studies. 443 
The effect of statins on in vitro virulence of some pathogens is interesting but again is hindered 444 
by the high concentrations required for significant results. However, this may be overcome by 445 
using sub-inhibitory concentrations of statins in combination with existing antibiotics. The 446 
evidence presented here regarding the repurposing of statins in combination therapies is 447 
promising but again may be statin / pathogen specific. While the most significant results have 448 
again been against intracellular bacteria there are few in vivo / clinical studies available against 449 
extracellular pathogens. When designing these studies however, the possibility of adverse effects 450 
associated with drug-drug- interactions should be an important consideration. 451 
Therefore, while overall clinical studies regarding the repurposing of statins as anti-microbials 452 
are inconclusive, the evidence presented here suggests further prospective studies focusing on 453 
statin and pathogen specificity, bacterial virulence, combinatorial therapy and/or means of drug 454 
administration are warranted. 455 
 456 
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Figure Legends 740 
Figure 1: Chemical structures of statins. A) Type 1 statins are characterised by a conserved 741 
lactone ring (blue), a decalin structure (black) and a butaryl side chain (red), which is different in 742 
each statin. B) Type 2 statins differ from type 1 statins due to the replacement of the butaryl side 743 
chain with a flurophenyl group (green), and although the lactone ring structure is conserved in all 744 
statins, the decalin group of Type 1 statins is replaced by a longer distinct side chain. Statins 745 
marked with an asterisk (*) are licensed to treat high cholesterol.  746 
 747 
Figure 2: Statins modulate bacterial growth and virulence. A) In vitro effects of statins on 748 
bacterial species. Statins reduce in vitro bacterial growth, motility and attachment. B) Key anti-749 
virulence mechanisms of statins. At physiological concentrations statin treatment can reduce 750 
bacterial invasion and translocation, in addition to inhibiting lipid raft production. The inhibition 751 
of Rho GTPase activity and cholesterol production by statins contribute to reduced bacterial 752 
virulence, decreased toxicity and impaired intracellular survival. C) At physiological 753 
concentrations statin treatment can reduce bacterial load and dissemination and increase bacterial 754 
clearance in mouse models of infection. 755 
 756 
 757 
 758 
 759 
 760 
 761 
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Table 1: MIC of statins against Gram-positive and Gram-negative bacteria 762 
  Statin MIC mg/l  
Bacteria Gram Sim Fluv Ator Ros Prav Ref 
S. Aureus pos       
 MSSA  16 - 63 ~200 42 - >250
208 - 
342 >250 
37, 39-
43 
MSSA clinical isolate  60.42 nt 52.08 341.67 nt 39 
MRSA  32 - 167 
~250 - 
>1024 
83 - 
>1024 
100 - 
>1024 
>250 - 
>1024 
37, 39-
40, 42-
43 
MRSA clinical isolate  116.67 nt 108.33 500 nt 39 
VISA group of strains  32 nt nt nt nt 42 
VRSA group of 
strains  32 - 64 nt nt nt nt 42 
S. epidermidis pos       
Type strains  26 - 32 nt 21 167 nt 39, 42 
Clinical isolate  35 nt 20 233 nt 39 
S. Pneumoniae pos       
Type strains  16 - 167 >123 104 333 >50 
38, 39, 
42 
Clinical isolate  292 nt 229 417 nt 39 
Enterococci pos       
VSE  50 - 52 300 83 - 250 
100 - 
333 nt 
37, 39, 
40 
VSE clinical isolate  292 nt 96 333 nt 39 
VRE  30 - 104 500 167 - 250 
100 - 
500 nt 
37, 39, 
40 
VRE clinical isolate  292 nt 217 500 nt 39 
E. faecalis group of 
strains  32 nt nt nt nt 42 
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S. pyogenes pos       
ATTC19615  62.5 nt 83.33 166.67 nt 39 
Clinical isolate  146 nt 133.33 275 nt 39 
L. monocytogenes pos       
 Group of strains   32 nt nt nt nt 42 
B. anthracis 
pos       
Type strains  16 nt nt nt nt 42 
        
H. influenza neg       
Clinical isolate  
146 - 
>250 nt 104 367 nt 38, 39 
ATTC29247  52 nt 83 167 nt 39 
Moraxella 
catarrhalis neg       
Clinical isolate  16 nt nt nt nt 38 
E. coli neg       
Type strains  
52 - 
>250 nt 26 - >250 104 >250 
39, 40, 
43 
O157:H7 ATCC 
700728  >256 nt nt nt nt 42 
Clinical isolate  112 nt 100 125 nt 39 
P. aeruginosa neg       
Type strains  
166 - 
>1024 >1024 
83 - 
>1024 
100 - 
>1024l 
>250 - 
>1024 
39, 40, 
42, 43, 
63 
Clinical isolate  121 nt 96 292 nt 39 
K. pneumoniae neg       
Type strains  
167 - 
>256 nt 167 333 nt 39, 42 
Clinical isolate  242 nt 217 258 nt 39 
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A. baumannii neg       
Type strains  
104 - 
>256 nt 16 333 nt 39, 42 
Clinical isolate  32 nt 22 300 nt 39 
C. freundii neg       
ATTC 8090  52 nt 83 167 nt 39 
Clinical isolate  133 nt 108 333 nt 39 
E. aerogenes neg       
ATTC 29751  26 nt 16 104 nt 39 
Clinical isolate  33 nt 20 183 nt 39 
P. mirabilis neg       
ATTC 12459  167 nt 63 250 nt 39 
Clinical isolate  146 nt 133 275 nt 39 
S. Tphimurium neg       
ATCC 700720  >256 nt nt nt nt 42 
 763 
Key: Sim, Simvastatin; Fluv, Fluvastatin; Ator, Atorvastatin; Ros, Rosuvastatin; Prav, 764 
Pravastatin; pos, Gram-positive; neg, Gram-negative; nt, not tested. 765 
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Table 2. Effect of statins on bacterial virulence  and antibiotic activity 766 
 Virulence trait       
 
Reduced 
biofilm 
formation 
Disrupt 
established 
biofilm Motility QS Protease 
T3SS 
ExoS 
Increased 
adhesion to 
human 
cells 
Reduced 
Invasion 
Trans-
location 
Toxin 
prodn 
 
 Statin (mg/l)        
Bacteria Sim Sim Sim/Lov/Mev Sim Sim  Mev Sim Sim Ref 
S. aureus 0.98 - 62.5 62.5 -    - - - - - 43 
 62.5 - -    - - - - - 41 
 - 64 -    - - -  40 40 42 
 - - -    - 0.04 - 
0.4 
- - - 66 
S.epidermitis - 128 -    - - - - - 42 
P. aeruginosa 4 & 40 - 40 NC  NC 4 NC - - - 63,64 
 - - -    - NC -   2 - 65 
Streptococcus - - -    - - 4 - - 67 
E.coli - - -    - - 4 - - 68 
B. cepacia - - - NC NC  - - - - - 70 
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 Antibiotic synergy       
 In vitro    In vivo 
(mice) 
   
Bacteria Antibiotic + statin Statin conc. Effect Antibiotic + 
statin 
Statin 
conc. 
Effect Ref 
Pneumococci  Pen + Sim 7.8  
Autolysis 
- - - 38 
MRSA/VRSA Mup/Fus/Dap + Sim <32  Growth  - - - 42 
S. aureus Van + Sim ? NC - - - 43 
M. tuberculosis Rif + Sim/Ator 0.2microM  Viability - - - 49 
    Rif, Pyr, iso 
+ sim 
25 
mg/kg/d 
 
bacillary 
killing 
78 
M. leprae Rif + Ator 0.2microM  Viability Rif + Ator 80 
mg/kg/d 
 
Viability 
49 
A. baumanii, Ami/Imi/Min + Prav/Sim/Ator/Fluv - NC - - - 79 
P. aeruginosa Cip/Cep/Pip + Ator/Fluv - NC - - - 79 
K. pneumoniae  Cip/Cep/Pip + Ator/Fluv - NC - - - 79 
E. coli Cip/Cep/Pip + Ator/Fluv - NC - - - 79 
 767 
Key: Statins: Sim, Simvastatin; Ator, Atorvastatin; Prav, Pravastatin; Fluv, Fluvastatin. Antibiotics: Pen, penicillin; Mup, mupirocin; 768 
Fus, fusidic acid; Dap, daptomycin; Van, vancomycin; Rif, rifampicin; Pyr, pyrazinamide; Iso, isoniazid; Ami, amikacin; Imi, 769 
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imipenem; Min, minocycline; Cip, ciprofloxacin; Cep, cefepime ; Pip, piperacillin 770 
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